Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.
All content for Pharmaceutical Industry: Past, Present and Future is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.
A Pharma perspective on healthcare needs and innovation in drug discovery
Pharmaceutical Industry: Past, Present and Future
57 minutes
16 years ago
A Pharma perspective on healthcare needs and innovation in drug discovery
The third Green Templeton Lecture 2009 explores how, by harnessing innovation to meet unmet medical needs, pharma companies can deliver significant value to patients, payers and shareholders. The Green Templeton Lectures 2009 explored the theme 'Addicted to Big Pharma? Reconciling business, medical and ethical needs' in a series of four lectures looking at the pharmaceutical industry past, present and future. This third lecture was delivered by Patrick Vallance (Head of Drug Discovery; GlaxoSmithKline) Philip Bloomer (Director of Campaigns; Oxfam)
Pharmaceutical Industry: Past, Present and Future
Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.
